<DOC>
	<DOC>NCT01758393</DOC>
	<brief_summary>This is a randomized, open-label, single-center clinical trial to compare the efficacy and safety profile for medium-dose versus high dose glucocorticoid in patients with IgG4-related Disease. Patients will be followed for three months to measure the primary outcome and secondary outcomes.</brief_summary>
	<brief_title>Glucocorticoids in Patients With IgG4-RD</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Males and females Age 1870 years old with informed consent Patients with IgG4RD: 1. swelling, sclerosing and inflammatory involvement of one or more organ, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions; 2. elevated serum IgG4 (&gt;1.35 g/L) 3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma cell infiltration (and IgG4+ plasma cells on immunohistology when performed); 4. exclusion of other diseases. Previously or currently received glucocorticoid and(or) immunomodulator Pregnancy or lactating Concurrent severe and/or uncontrolled and/or unstable diseases Patient with malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>IgG4-related disease</keyword>
	<keyword>IgG4-RD</keyword>
</DOC>